A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer (NCT02152631)

🧪 Interventions in This Study

• Abemaciclib (DRUG)
• Erlotinib (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (231 Sites)

Showing the first 25 of 231 sites.

• Highlands Oncology Group — Fayetteville, Arkansas
• St. Bernards Medical Center — Jonesboro, Arkansas
• City of Hope National Medical Center — Duarte, California
• University of California - San Diego — La Jolla, California
• Loma Linda University School of Medicine — Loma Linda, California
• CBCC Global Research, Inc. — Los Angeles, California
• Central Coast Medical Oncology Corporation — Los Angeles, California
• Fort Wayne Oncology & Hematology — Los Angeles, California
• SMO TRIO -Translational Research — Los Angeles, California
• St. Joseph Heritage Medical Group — Los Angeles, California
• UCLA Department of Medicine-Hematology/Oncology — Los Angeles, California
• Cancer Care Associates Medical Group — Los Angeles, California
• Dignity Health Care Institute — Sacramento, California
• Alegent Immanuel Cancer Center — Englewood, Colorado
• Jewish Hospital — Englewood, Colorado
• Oncology Hematology West — Englewood, Colorado
• SMO Catholic Health Initiatives — Englewood, Colorado
• St Joseph Cancer Center — Englewood, Colorado
• St. Francis Medical Center — Englewood, Colorado
• Medical Oncology Hematology Consultants — Newark, Delaware
• Boca Raton Regional Hospital — Boca Raton, Florida
• Halifax Medical Center — Daytona Beach, Florida
• Memorial Cancer Institute — Pembroke Pines, Florida
• H Lee Moffitt Cancer Center — Tampa, Florida
• University Cancer & Blood Center, LLC — Athens, Georgia

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Non Small Cell Lung Cancer

• The Transitions Project: Supporting Adults During the Shift From Cancer Treatment to Surveillance — Boston, Massachusetts
• A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer — Middletown, New Jersey
• Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC — Beverly Hills, California
• Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer — Columbus, Georgia
• Assessment of Precision Irradiation in Early NSCLC and Interstitial Lung Disease — Edmonton, Alberta
• A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer — Springdale, Arkansas

Explore by condition: All Non Small Cell Lung Cancer clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.